Researchers from Southern Medical University and affiliated organizations assessed the molecular mechanisms behind TGF-β-induced fibrosis in ovarian endometrioma.
Investigators from CMR Curediab Metabolic Research GmbH recently disclosed preclinical data for a novel hepatoprotective thioacrylamide compound, HK-3, being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Scientists from the Karolinska Institute have found two different types of cells that give rise to the fibroblasts that form fibrotic scars after spinal cord injury (SCI) depending on their location. In a study in mice, the researchers observed that pericytes acted in lesions that affect the gray matter and perivascular fibroblasts acted in the white matter.
Chronic kidney disease (CKD) during diabetes may manifest several phenotypes, including diabetic nephropathy (DN), nondiabetic renal disease (NDRD) or a mixed form.
Researchers from Shanghai Jiao Tong University presented findings from a study that aimed to assess the metabolic landscape of intestinal fibrosis in Crohn’s disease.
Scientists from the Centre for Genomic Regulation and collaborators have developed a new approach to limiting the amount of collagen produced by hyperactive fibroblasts, which could lead to effective treatments for fibrotic diseases and scarring.
Evotec SE and Variant Bio Inc. have signed a collaboration agreement to identify treatments for diseases caused by fibrosis. The partnership leverages Variant Bio’s genomic discovery capabilities and VB-Inference platform as well as Evotec’s expertise in antifibrotic drug discovery.
A small molecule could provide a new therapeutic approach against organ fibrosis. Using genome-wide association (GWA) assays, a group of researchers from the Westmead Institute for Medical Research in Sydney identified Mer tyrosine kinase (MERTK) as a candidate to study fibrosis and showed that its inhibition with the experimental compound reduced this condition in mouse models’ liver, kidneys and lungs. “There were some studies on the role of MERTK in liver fibrosis, but its therapeutic potential for various organ fibrosis has not been explored before. This study provides unequivocal evidence that MERTK is a potent nodal regulator of fibrosis supported by detailed mechanistic studies,” the senior author Mohammed Eslam told BioWorld.
Researchers from Catholic University of Korea published data from a study that investigated the effect of miRNA-21a-5p on fibrosis development in systemic sclerosis (SSc). With the aim of assessing the pathological impact of miRNA-21a-5p on skin and lung fibrosis in vivo, a bleomycin-induced SSc murine model was developed, and the mice were hydrodynamically injected with plasmids containing pre-miRNA-21a-5p or anti-miRNA-21a-5p.
University of Nebraska has described SF-2523 derivatives acting as dual inhibitors of bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) and phosphatidylinositol 3-kinase (PI3K) reported to be useful for the treatment of medulloblastoma and fibrosis.
